Comparative activities of TR-700 (Torezolid) against staphylococcal blood isolates collected in spain

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 2212-2215

  Betriu, Carmen ^a   Morales, Gracia ^a   Rodríguez Avial, Icíar ^a   Culebras, Esther ^a   Gómez, María ^a   López Fabal, Fátima ^a   Picazo, Juan J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DAPTOMYCIN; LINEZOLID; OXACILLIN; OXAZOLIDINONE DERIVATIVE; TEICOPLANIN; TOREZOLID; TR 700; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATE; BLOOD SAMPLING; BLOODSTREAM INFECTION; DRUG POTENCY; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPAIN; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; SEPSIS; SPAIN; STAPHYLOCOCCAL INFECTIONS; TETRAZOLES; VANCOMYCIN;

EID: 77951217660     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01653-09     Document Type: Article

References (19)

1. CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 8th ed., vol. 29, no. 2. CLSI document M7-A8. CLSI, Wayne, PA.
2. CLSI. 2009. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement, vol. 29, no. 3. CLSI document M100-S19. CLSI, Wayne, PA.
3. de la Torre, M., M. Sánchez, G. Morales, E. Baos, A. Arribi, N. García, R. Andrade, B. Peláez, M. P. Pacheco, S. Domingo, J. Conesa, M. Nieto, F. J. Candel, and J. J. Picazo. 2008. Outbreak of linezolid-resistant Staphylococcus aureus in intensive care. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C2-1835a.
4. Gales, A. C., H. S. Sader, S. S. Andrade, L. Lutz, A. Machado, and A. L. Barth. 2006. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int. J. Antimicrob. Agents 27:300-302.
5. Hentschke, M., B. Saager, M. A. Horstkotte, S. Scherpe, M. Wolters, H. Kabisch, R. Grosse, P. Heisig, M. Aepfelbacher, and H. Rohde. 2008. Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain. Infection 36:85-87.
6. Jones, R. N., S. Kohno, Y. Ono, J. E. Ross, and K. Yanagihara. 2009. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn. Microbiol. Infect. Dis. 64:191-201.
7. Jones, R. N., G. J. Moet, H. S. Sader, R. E. Mendes, and M. Castanheira. 2009. TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. J. Antimicrob. Chemother. 63:716-720.
8. Jones, R. N., J. E. Ross, J. M. Bell, U. Utsuki, I. Fumiaki, I. Kobayashi, and J. D. Turnidge. 2009. Zyvox annual appraisal of potency and spectrum program: linezolid surveillance program results for 2008. Diagn. Microbiol. Infect. Dis. 65:404-413.
9. Kehrenberg, C., and S. Schwarz. 2006. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob. Agents Chemother. 50:1156-1163.
10. Livermore, D. M., S. Mushtaq, M. Warner, and N. Woodford. 2009. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J. Antimicrob. Chemother. 63:713-715.
11. Locke, J. B., M. Hilgers, and K. J. Shaw. 2009. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob. Agents Chemother. 53:5275-5278.
12. Locke, J. B., M. Hilgers, and K. J. Shaw. 2009. Novel ribosomal mutations in Staphylococcus aureus identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob. Agents Chemother. 53:5265-5274.
13. Meka, V. G., H. S. Gold, A. Cooke, L. Venkataraman, G. M. Eliopoulos, R. C. Moellering, Jr., and S. G. Jenkins. 2004. Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus. J. Antimicrob. Chemother. 54:818-820.
14. Mendes, R. E., L. M. Deshpande, M. Castanheira, J. DiPersio, M. A. Saubolle, and R. N. Jones. 2008. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52:2244-2246.
15. Morales, G., J. J. Picazo, E. Baos, F. J. Candel, A. Arribi, B. Peláez, R. Andrade, M. A. de la Torre, J. Fereres, and M. Sánchez-García. 2010. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin. Infect. Dis. 50: 821-825.
16. Prokocimer, P. 2008. Human pharmacokinetics of the prodrug TR-701 and TR700, its active moiety, after multiple oral doses of 200 and 400 mg TR-701, a novel oxazolidinone. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-2064.
17. Schaadt, R., D. Sweeney, D. Shinabarger, and G. Zurenko. 2009. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob. Agents Chemother. 53:3236-3239.
18. Shaw, K. J., S. Poppe, R. Schaadt, V. Brown-Driver, J. Finn, C. M. Pillar, D. Shinabarger, and G. Zurenko. 2008. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob. Agents Chemother. 52:4442-4447.
19. Toh, S. M., L. Xiong, C. A. Arias, M. V. Villegas, K. Lolans, J. Quinn, and A. S. Mankin. 2007. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol. 64:1506-1514.